Legal support for intellectual-property rights is essential to innovation. In health care, patents protect intellectual property in pharmaceutical innovation. Not all countries respect pharma IP equally, according the Global IP Index.
India has long been a problem because of its successful generic drug industry. Generic drug makers make copies of brand-name drugs once their patents have expired. This means that they have an incentive to lobby for weaker patents. If the political economy of a country’s pharmaceutical industry is dominated by generic competitors, it is difficult for innovative companies to gain a foothold.
One Indian innovative drug maker is speaking out.
Read the entire article at NCPA's Health Policy Blog.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment